Physician profile
John Law
NPI 1740259761
$34,859.79
in general payments reported to CMS, 2019-2025
67 companies · $1,926 in 2025
The $1,926 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $1,262 · 2021: $3,731 · 2022: $2,476 · 2023: $2,222 · 2024: $2,173 · 2025: $1,926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,320.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $21,946.00 | 2019-2025 | |
| Abbvie INC. | $1,561.09 | 2021-2025 | |
| Novo Nordisk INC | $1,331.20 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,154.90 | 2019-2025 | |
| Lilly USA, LLC | $743.18 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $679.94 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $618.03 | 2019-2025 | Repatha, Otezla, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $617.59 | 2019-2024 | Jardiance, Ofev |
| Abbott Laboratories | $469.40 | 2021-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $414.07 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Glaxosmithkline, LLC. | $376.59 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Amarin Pharma, INC. | $349.09 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $329.33 | 2022-2025 | Rexulti |
| Lundbeck LLC | $306.18 | 2019-2025 | Rexulti, Vyepti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $270.16 | 2022-2025 | Caplyta |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Law listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.